In the future, refining stapled peptides inhibitors to interrupt WASF3-dependent immunocomplex or identifying novel WASF3 transcript inhibitors using genome-editing tools would facilitate the development of more effective therapeutics to improve clinical outcomes in metastatic cancers. Here, WASF3 is linked to metastatic malignant neoplasm.